Lupus & antiphospholipid syndrome
Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis
Authors' conclusion
Although the comparative efficacy between telitacicept and belimumab remains statistically inconclusive, cost-effectiveness modelling suggests that telitacicept plus standard therapy is likely to be a cost-effective treatment option for patients with SLE in China under current WTP thresholds.
Study context
- Population
- Patients with active systemic lupus erythematosus (SLE) in China5 RCTs
- Comparison
- Telitacicept vs belimumab
- Outcome
- Cost-effectiveness: Life years (LYs), QALYs, total healthcare costs and ICER
- Follow-up
- Lifetime
Methodological detailsmicrosimulation model, lifetime horizon, Chinese societal perspective, sensitivity analyses
- Microsimulation model
- Lifetime horizon
- Chinese societal perspective
- Sensitivity analyses
Pooled result
As reported in the abstract
Cost-effectiveness, baseline analysis
Incremental quality-adjusted LYs (QALYs)
0.506 QALYs
Telitacicept
Incremental total cost
US$3026
Telitacicept
Incremental cost-effectiveness ratio (ICER)
US$5984 per QALY gained
Telitacicept
- Probability telitacicept cost-effective at willingness-to-pay (WTP) threshold of US$40 344 per QALY
- 99.1%
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Response rate (NMA) | 1.200 (0.760–1.910) | |
| 0.512Relative risk (log scale) |
Original publication
Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis. Lupus Sci Med. Published 16 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →